We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+13%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$10.5B
AUM Growth
+$923M
Cap. Flow
+$224M
Cap. Flow %
2.14%
Top 10 Hldgs %
34.54%
Holding
153
New
17
Increased
27
Reduced
30
Closed
10

Top Buys

Rank Stock Value
1
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$170M
2
AET
Aetna Inc
AET
+$79.5M
3
UHS icon
Universal Health Services
UHS
+$75.3M
4
KALA icon
KALA BIO
KALA
+$52.2M
5
IMMU
Immunomedics Inc
IMMU
+$50.5M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$185M
2
EW icon
Edwards Lifesciences
EW
+$51.3M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$50.6M
4
INSM icon
Insmed
INSM
+$48M
5
GKOS icon
Glaukos
GKOS
+$34.4M

Sector Composition

Rank Sector Weight
1 Healthcare 91.18%
2 Financials 2.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
26
BeOne Medicines Ltd
ONC
$34B
$136M 1.3%
1,313,788
+26,200
+2% +$1.95M
ALNY icon
27
Alnylam Pharmaceuticals
ALNY
$38.2B
$127M 1.22%
1,084,800
+445,600
+70% +$38M
ASND icon
28
Ascendis Pharma A/S
ASND
$16.7B
$122M 1.17%
3,367,315
– –
BOLD
29
DELISTED
Audentes Therapeutics, Inc
BOLD
$116M 1.11%
4,129,638
-672,000
-14% -$14.6M
VTRS icon
30
Viatris
VTRS
$20.8B
$113M 1.08%
3,601,100
+621,900
+21% +$21.1M
JAZZ icon
31
Jazz Pharmaceuticals
JAZZ
$16.2B
$110M 1.05%
749,200
+203,300
+37% +$30.7M
SEM
32
DELISTED
Select Medical
SEM
$107M 1.02%
10,353,696
+3,509,882
+51% +$32.4M
TMO icon
33
Thermo Fisher Scientific
TMO
$213B
$101M 0.97%
534,200
– –
JUNO
34
DELISTED
Juno Therapeutics, Inc.
JUNO
$91.6M 0.88%
2,041,608
+1,126,400
+123% +$38.4M
IRWD icon
35
Ironwood Pharmaceuticals
IRWD
$601M
$90.8M 0.87%
6,876,485
– –
PFE icon
36
Pfizer
PFE
$143B
$87.8M 0.84%
2,591,575
– –
CRVS icon
37
Corvus Pharmaceuticals
CRVS
$1.12B
$85.7M 0.82%
5,379,349
– –
ILMN icon
38
Illumina
ILMN
$29.5B
$79.4M 0.76%
409,658
– –
AGN
39
DELISTED
Allergan plc
AGN
$76.6M 0.73%
373,590
– –
MGLN
40
DELISTED
Magellan Health Services, Inc.
MGLN
$76.2M 0.73%
882,600
-332,500
-27% -$26.2M
UNH icon
41
UnitedHealth
UNH
$383B
$74.4M 0.71%
380,000
-48,600
-11% -$9.39M
GBT
42
DELISTED
Global Blood Therapeutics, Inc.
GBT
$74.3M 0.71%
2,393,635
+221,700
+10% +$6.23M
UHS icon
43
Universal Health Services
UHS
$10.2B
$74.2M 0.71%
+669,000
New +$75.3M
AERI
44
DELISTED
Aerie Pharmaceuticals
AERI
$69.9M 0.67%
1,438,182
-393,465
-21% -$21.5M
BMRN icon
45
BioMarin Pharmaceuticals
BMRN
$11.9B
$69.2M 0.66%
743,900
-238,700
-24% -$21.1M
MDT icon
46
Medtronic
MDT
$113B
$68.4M 0.65%
879,000
– –
BLUE
47
DELISTED
bluebird bio
BLUE
$66.2M 0.63%
37,206
+6,341
+21% +$8.86M
NTLA icon
48
Intellia Therapeutics
NTLA
$1.54B
$66.2M 0.63%
2,662,180
– –
AGN.PRA
49
DELISTED
Allergan plc
AGN.PRA
– –
0
– –
SHPG
50
DELISTED
Shire pic
SHPG
$61.2M 0.59%
399,908
-148,900
-27% -$23.3M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2017 Portfolio in Review

As of Q3 2017, OrbiMed held 153 positions worth $10.5B, up 9.7% from $9.54B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed's Q3 2017 filing shows 17 new, 27 increased, 30 reduced and 10 closed positions. Its largest new stake was Clementia Pharmaceuticals Inc.: 10,425,225 shares worth $176M. The largest sale was Humana, an estimated $185M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 93% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q3 2017 buy was Clementia Pharmaceuticals Inc.: 10,425,225 shares worth $176M.
  • OrbiMed added most to Aetna Inc in Q3 2017, an estimated $79.5M increase.
  • OrbiMed's biggest Q3 2017 reduction was Edwards Lifesciences, cutting an estimated $51.3M.
  • OrbiMed fully exited Humana in Q3 2017, selling an estimated $185M.
  • OrbiMed's ten largest holdings make up 35% of its $10.5B portfolio in Q3 2017.
  • OrbiMed opened 17 new positions and closed 10 in Q3 2017.
  • OrbiMed's portfolio value rose 9.7% quarter-over-quarter to $10.5B.

Based on OrbiMed's 13F filing for Q3 2017, filed 14 Nov 2017.